HuoShi Creation Launches AI-Powered Intelligent Investment Attraction Solution for Biopharma Industry, Files IPO Prospectus

VCBeat (WeChat ID: vcbeat) has learned that on December 1, the Seminar on Digital Investment Promotion for China’s Biopharmaceutical Industry was held in Hangzhou. At the event, Huoshi Chuangzao officially launched its intelligent investment promotion solution for the biopharmaceutical industry, powered by big data and artificial intelligence.

According to data from Huoshi Chuangzao, the number of enterprises in China's life and health industry has grown from 599,000 five years ago to 2.198 million to date. Core industrial clusters are accelerating their formation, including the Yangtze River Delta, the Pearl River Delta, the Beijing-Tianjin-Hebei region, and the central and western regions centered on the Hunan-Hubei area and the Chengdu-Chongqing economic circle. Moreover, among the 168 national high-tech zones across China, more than 50 have designated the biopharmaceutical industry as their primary industrial sector.

Data shows that China’s biopharmaceutical industry market exceeds RMB 10 trillion. It is not only vast in scale but also encompasses numerous subsectors, with innovative drugs, medical devices, in vitro diagnostics (IVD), gene therapy, and cell therapy entering a golden decade of development.

Undoubtedly, the biomedical industry boasts a vast market, numerous subsectors, rapid growth, and significant potential. While the industry’s trajectory is positive, it is particularly critical for industrial parks to seize this development opportunity, pursue differentiated growth strategies, and achieve both rapid and high-quality expansion.

In this regard, Jin Xia, Chairman of Firestone Creation, stated that cities and industrial parks serve as the core carriers for the clustered development of the biopharmaceutical industry. Data-driven specialized construction of industrial parks is a crucial approach for regional biopharmaceutical sectors to address industrial competition, achieve high-quality and rapid growth, and even overtake competitors by adopting new development pathways. The advancement of new technologies such as big data and artificial intelligence has provided governments and industrial parks with broader channels, more comprehensive information, and more open-minded strategies for investment promotion.

Leveraging deep insights into the biopharmaceutical industry, Huoshi Chuangzao has developed data-driven investment promotion tools that enable practitioners to monitor real-time intelligence, accurately acquire leads, identify suitable enterprises at the right time, formulate precise strategies based on companies’ relocation drivers, and implement monitoring and early-warning systems for landed projects to ensure high-quality post-investment services. More importantly, from the perspective of industrial synergy, it helps urban industrial parks identify directions for clustered development, efficiently attract high-quality enterprises and key talent, enhance upstream and downstream social collaboration through high-level industrial agglomeration, build distinctive industrial clusters, and thereby achieve precise investment promotion along the industrial chain.

What Are the Pain Points in Industry Investment Promotion? According to the "Special Survey on Investment Promotion in the Biopharmaceutical Industry" by Huoshi Chuangzao, each investment promotion manager secures fewer than one project per year on average. Additionally, recruitment and training of investment promotion personnel are challenging, and staff turnover rates are high.

Many senior investment promotion professionals from government industrial parks stated on-site that relying solely on their in-house teams, constrained by limitations in manpower, energy, capacity, and professional networks, has led to suboptimal results in attracting investment, seriously impeding regional economic development. Furthermore, when facing millions of biopharmaceutical companies, the ability to rapidly identify well-matched targets and access detailed company information is a critical factor in enhancing the efficiency of investment promotion efforts.

Huoshi Chuangzao believes that the drivers behind investment site selection for biopharmaceutical enterprises vary across different stages of their lifecycle. By digitizing both the corporate lifecycle and product cycle, advanced algorithmic technologies can intelligently predict the motivations behind corporate investment and relocation decisions.

At the launch event, Dr. Hu Ruomei, Vice President of Firestone Creation, provided a comprehensive introduction to Firestone Creation’s Intelligent Investment Promotion Solution for the Biopharmaceutical Industry. Centered around three core product lines—the Intelligent Investment Promotion SaaS PC platform, the Intelligent Investment Promotion SaaS mini-program, and the Pharma Site Selection Platform—the solution offers government industrial parks end-to-end investment promotion services. These services include investment strategy and policy research, thematic seminars on specialized sectors, digital investment promotion training, customized investment promotion management systems, and evaluation of proposed investment projects. The initiative aims to establish a precise model for industrial development and drive the clustering of biopharmaceutical industries through data-driven insights.

Specifically, the SaaS PC platform and the Intelligent Investment Promotion SaaS mini-program can customize intelligent recommendation and prediction models based on the actual resource endowments of government industrial park clients and their key investment promotion priorities, thereby precisely screening enterprises in specific industry segments and of varying scales. The enterprise site selection platform standardizes site selection requirement information and accurately matches government industrial parks’ investment promotion preferences through digital enterprise profiling.

Currently, Huoshi Chuangzao has developed over 40 precise prediction models and generated 3,000 valid investment promotion leads, enabling direct contact with corporate site-selection decision-makers within 48 hours. It is reported that entities such as the Shijiazhuang High-Tech Industrial Development Zone, the Cangzhou Lingang Economic and Technological Development Zone, and the Zhongguancun Development Group are leveraging Huoshi Chuangzao’s support to implement digital and intelligent investment promotion initiatives. During the first month of its trial operation in the Shijiazhuang High-Tech Industrial Development Zone, the platform helped identify nearly 200 valid leads; among these, 15 companies expressed willingness to conduct on-site visits at an opportune time, while 124 opted for preliminary review based on park documentation. In the first week of its trial operation in the Cangzhou Lingang Economic and Technological Development Zone, the platform helped uncover 49 valid leads; of these, 4 companies indicated their interest in future site visits, and 23 chose to gain initial insights through park materials.

It is worth highlighting that “Yao Xuanzhi” (Pharma Site Selector), the corporate site selection platform under Huoshi Chuangzao’s intelligent investment promotion solution, made its debut. Yao Xuanzhi is a WeChat mini-program developed by Huoshi Chuangzao for pharmaceutical and medical device companies, offering precise industrial park matching and investment site selection advisory services. It serves as an efficient and professional tool to achieve a closed-loop ecosystem in industrial investment promotion.

Yao Xuanzhi meets the needs of online promotion of park highlights. Corporate executives can use Yao Xuanzhi to centrally access basic information on various industrial parks and directly connect online with investment promotion personnel from parks of interest. As enterprises are the main entities in the biopharmaceutical industry, the difficulty of site selection urgently needs to be addressed. Yao Xuanzhi fulfills the critical demand for fast, accurate, and cost-effective site selection, helping companies reduce the average site-selection timeline from 6–12 months to 1–3 months, narrow down visits from over a dozen parks to precise recommendations and matchmaking with just 3–4 parks, and truly enhance efficiency by shifting the responsibility from an entire management team to a single management-level colleague.

“Let data do the running, so we take fewer detours.” Positioning in the biopharmaceutical industry no longer relies on guesswork; sourcing biopharmaceutical projects no longer depends on indiscriminate conference or door-to-door canvassing; promoting biopharmaceutical parks no longer hinges on printed materials; securing approval for biopharmaceutical projects no longer rests on storytelling; and investment promotion management in the biopharmaceutical sector no longer leans on Excel spreadsheets. It is foreseeable that, with the launch of Huoshi Chuangzao’s intelligent investment promotion solution for the biopharmaceutical industry, an intelligent era of data-driven investment promotion has arrived.

On the same day, the Economic Cooperation Bureau of Dongpo District in Meishan City, the Preparatory Group for Guang’an Pharmaceutical High-Tech Zone, Zhongke Airport Urban Jingyang Industrial Investment Co., Ltd., and Huoshi Chuangzao also entered into a strategic signing agreement.